91271-79-3

Usage

Uses

Used in Pharmaceutical Industry:
4-(PYRROLIDIN-1-YLMETHYL)BENZYLAMINE is used as a therapeutic agent for the treatment of various psychiatric and neurological disorders, such as depression, anxiety, and obsessive-compulsive disorder, due to its SSRI properties that modulate serotonin levels in the brain.
Used in Research Applications:
4-(PYRROLIDIN-1-YLMETHYL)BENZYLAMINE is used as a research compound to investigate its precise mechanisms of action and potential therapeutic uses, as well as to explore its psychoactive effects and potential for abuse, contributing to the development of safer and more effective treatments for mental health conditions.

InChI:InChI=1/C12H18N2/c13-9-11-3-5-12(6-4-11)10-14-7-1-2-8-14/h3-6H,1-2,7-10,13H2

Upstream product

• 78064-96-7 4-(pyrrolidin-1-ylmethyl)benzonitrile 
• 105-07-7 4-cyanobenzaldehyde 

Downstream Products

• 1414782-04-9 N-(4-(pyrrolidin-1-ylmethyl)benzyl)-2-amino-4-nitrobenzamide 
• 1414782-03-8 7-nitro-3-(4-(pyrrolidin-1-ylmethyl)benzyl)quinazolin-4(3H)-one 
• 1414781-98-8 C₂₉H₂₆ClN₅O 
• 1414782-05-0 7-amino-3-(4-(pyrrolidin-1-ylmethyl)benzyl)quinazolin-4(3H)-one 
• 1272465-64-1 C₃₁H₄₅N₅O₇ 

Relevant academic research and scientific papers

Mimicking the intramolecular hydrogen bond: Synthesis, biological evaluation, andmolecular modeling of benzoxazines and quinazolines as potential antimalarial agents

The intramolecular hydrogen bond formed between a protonated amine and a neighboring H-bond acceptor group in the side chain of amodiaquine and isoquine is thought to play an important role in their antimalarial activities. Here we describe isoquine-based

6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS

The present invention provides 6-substituted 2,3,4,5-tetrahydro-lH- benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is -NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.

New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture

The present invention relates to carboxamide compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1, R2, R3 and k have the meanings given in claim 1. Moreover the invention relates to process for preparing the above mentioned carboxamides as well as pharmaceutical compositions containing at least one carboxamide according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.